Dr. Aref Al-Kali, MD

Dr. Al-Kali practices at Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic.

Dr. Al-Kali's NPI, 1598732877, was assigned on March 5, 2006. Dr. Al-Kali graduated from Damascus University Faculty of Medicine in 2000. Dr. Al-Kali's Minnesota license number on file is 52918.

Dr. Al-Kali's primary practice is Mayo Clinic Hospital, Saint Marys Campus, at 1216 Second Street Southwest, Rochester, MN 55902 in Olmsted County. The practice phone is (507) 255-5123.

Dr. Al-Kali's primary practice is Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic. Dr. Al-Kali is also affiliated with Mayo Clinic Health System in Albert Lea. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Al-Kali to 1 more hospital and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al-Kali practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Al-Kali's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Al-Kali is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Al-Kali's licenses on file in 5 states: Minnesota, Connecticut, Oklahoma, Texas and Ohio.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Al-Kali treats.

CMS data shows 3,383 Medicare services from Dr. Al-Kali across 14 procedure codes in 2024, for 279 Medicare patients. Medicare paid $77,375 for them.

CMS counts 279 Medicare patients who saw Dr. Al-Kali in 2024. The largest group is 65 to 74, with 142 patients. 73% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Al-Kali's median patient age at 74, with 49% women.

In 2024, Dr. Al-Kali wrote 331 Medicare Part D claims for 75 patients. 64% of them were for generic drugs. CMS names the drug for 226 of them, across 12 drugs with 11 or more claims each, at $889,508 in total drug cost. In 2023, CMS named 112 claims across 3 drugs.

Dr. Al-Kali accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Al-Kali as offering telehealth.

Dmand AI links 209 papers to Dr. Al-Kali, published from 2008 to 2025. 2022 was the busiest year, with 26. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Myeloproliferative Disorders. Dr. Al-Kali has published most often in Am J Hematol. Dr. Al-Kali's most frequent co-authors are Mark R. Litzow, MD, Ayalew Tefferi, MD and Kebede H. Begna, MD.

Dmand AI links Dr. Al-Kali to 6 clinical trials, 4 of them phase 2 studies. Conditions studied include Myelodysplastic Syndromes, Anemia, Refractory, with Excess of Blasts and Chromosome 8, trisomy. Traws Pharma, Inc. sponsors the most, 3. Open Payments lists research payments to Dr. Al-Kali that name 1 trial.

CMS Open Payments shows 1 general payment to Dr. Al-Kali from 1 drug or device company in 2022. Consulting fees make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $4,050. It also lists 10 research payments totaling $16,433 in 2016, naming 1 clinical trial.

Dmand AI lists 5 awards for Dr. Al-Kali, most recently Internal Medicine Resident Top Educators in 2012. Dr. Al-Kali serves on NCCN MDS committee.

Dr. Al-Kali graduated from Damascus University Faculty of Medicine in 2000. Dr. Al-Kali is a member of ACP, ASCO and ASH.

Dr. Al-Kali is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.